In a report released yesterday, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on VolitionRX (VNRX – Research Report), with a price target of $2.50. The company’s shares closed yesterday at $0.79.
According to TipRanks, Osborn is an analyst with an average return of -16.9% and a 26.25% success rate. Osborn covers the Healthcare sector, focusing on stocks such as Avita Medical, Sanara MedTech, and Lucid Diagnostics.
Currently, the analyst consensus on VolitionRX is a Moderate Buy with an average price target of $2.50.
VNRX market cap is currently $65.17M and has a P/E ratio of -1.72.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VolitionRX (VNRX) Company Description:
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Austin, TX.
Read More on VNRX:
- VolitionRx reports Q1 revenue $170,000, consensus $390,000.
- VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update
- Is VNRX a Buy, Before Earnings?
- VolitionRX Announces Board Reshuffle and Bylaws Amendment
- VolitionRx launches Nu.Q Vet Cancer Test in-clinic in U.S. and Europe
